VEGF-A

Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
Premium

This article has been updated to clarify the enrollment challenges with the InVite Study.

FDA Rejects Avastin as Breast Cancer Drug; Genentech to Conduct New Trial to ID Best Responders
Premium

Originally published Nov. 18. By Turna Ray

ACT Biotech Investigating Predictive Biomarkers for VEGF Inhibitor Telatinib in Gastric Cancer
Premium

New VEGF Biomarker Data Illustrates Complexities of Personalizing Anti-Angiogenic Drugs
Premium

'Middle Ground' Avastin Proposal Could Maintain Access for Molecularly Defined Breast Cancer Patients
Premium

Originally published Aug. 16. By Turna Ray

Jun 30, 2011

FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
Premium

Jun 29, 2011

Despite Passionate Patient Accounts, FDA Sees No Evidence of 'Super-Responders' in Avastin Trials
Premium

Mar 2, 2011

Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
Premium